Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01433419 | Open-label Study of TAK-875 | PHASE3 | COMPLETED | 333 | — | — | Jan 1, 2012 | Dec 1, 2012 | Mar 22, 2013 | 31 | Japan |
| NCT01433406 | Long-term Study of TAK-875 | PHASE3 | COMPLETED | 1,222 | — | — | Oct 1, 2011 | Dec 1, 2013 | Jan 27, 2014 | 71 | Japan |
| NCT01433393 | Double-blind Comparative Study of TAK-875 | PHASE3 | COMPLETED | 192 | — | — | - | Sep 1, 2012 | Nov 9, 2012 | 19 | Japan |
| Arm | Type | Description |
|---|---|---|
| TAK-875 25 mg | EXPERIMENTAL | - |
| TAK-875 50 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TAK-875 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. The participant is an outpatient. 2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. Exclusion Criteria: 1. The participant has any serious cardiac disease, serious cere...